Opinion|Videos|March 28, 2024
Patient Scenario Cont’d: Treatment in Late-Line Relapsed MM
Turning the focus back to the clinical scenario, Donna Catamero, ANP-BC, OCN, CCRC, discusses the patient’s repeat diagnostic workup and the panel provides their insights on treatment decisions.
Advertisement
Episodes in this series
Advertisement
Related to this article
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
3
Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC
4
Top 3 Poster Takeaways in Liver Cancer Care From The Liver Meeting 2026
5